[Mar-2022] RAPS RAC-GS DUMPS WITH REAL EXAM QUESTIONS
2022 New Lead2Passed RAC-GS PDF Recently Updated Questions
NEW QUESTION 60
Which of the following BEST describes the content of the "Physical, Chemical, and Pharmaceutical
Properties and Formulation" section of an IB?
- A. A brief summary of relevant physical, chemical, and pharmaceutical properties: instructions for storage
and handling of the dosage form: and a description of the formulation - B. A detailed summary of the physical and chemical properties of the drug product with a signed expert
statement addressing the suitability and stability of the formulation for its intended use - C. A description and flow chart illustrating the synthetic route for the active ingredient and the preparation
method of the finished product - D. A review of available data to support the determination of the chemical structure and physical attributes
of the drug substance plus batch analysis and stability data for the finished formulation
Answer: A
NEW QUESTION 61
In preparation for the development of a new line of products, a regulatory affairs professional is asked to
prepare a short presentation for senior management. Which of the following topics is MOST important to
cover?
- A. Capacity of the manufacturing facilities to fully produce the new product
- B. Potential clinical sites for the Phase III clinical trial
- C. Previous actions taken by regulatory authorities on similar products
- D. Regulatory requirements for labeling and packaging
Answer: C
NEW QUESTION 62
Company X is planning to acquire the rights for a product marketed by Company Y. As part of due
diligence, what is the MOST important information the Company X regulatory affairs professional should
ask senior management to request from Company Y?
- A. Marketing materials
- B. Safety issues
- C. Clinical trial data
- D. Intellectual properly
Answer: B
NEW QUESTION 63
Company X encounters challenges in the global life cycle management of its medical devices. Which of
the following Is MOST appropriate for improving product life cycle management?
- A. Identify countries where special requirements exist during the product development phase.
- B. Plan regulatory approval update meetings with senior management and stakeholders.
- C. Initiate a global submission process after all submission data are finalized.
- D. Utilize the STED template to complete global requirements.
Answer: A
NEW QUESTION 64
According to the ICH guideline on GMP for API, to which of the following is the MOST stringent
requirement applied?
- A. Introduction of the API starting material
- B. Production of Intermediate(s)
- C. Isolation and purification
- D. Physical processing and packaging
Answer: D
NEW QUESTION 65
Company X acquires Company Y. Both companies produce pharmaceuticals distributed globally. A
regulatory authority requires that all labeling for Company Y's products be converted to Company X within
three months. The regulatory affairs professional at Company X concludes that it is not feasible to meet
this request within the time frame.
Which is the FIRST step that the regulatory affairs professional at Company X should take to address the
situation?
- A. Request additional resources from senior management in order to complete the labeling conversion
within the time frame given by the regulatory authority. - B. Convene an urgent meeting with internal stakeholders to inform them of the regulatory authority
requirement and assign responsibilities. - C. Submit as many labeling conversion applications as possible within the time frame and request an
extension for the remaining ones. - D. Develop a plan of action with tasks, timelines, and responsibilities and request an extension period
from the regulatory authority.
Answer: D
NEW QUESTION 66
One month prior to the anticipated approval date for your product, the marketing application that you
submitted to a major regulatory authority has become the subject of an advisory committee meeting of
experts convened by the regulatory authority. The advisory committee members unanimously vote not to
approve your product because of a safety concern. Two days after the advisory committee meeting, the
regulatory authority requests additional information to support the safety of your product. Assuming you
have no additional data to provide, which of the following would be your MOST appropriate response to
the regulatory authority's request?
- A. "We disagree with the advisory committee's decision because the committee neglected the thorough
safety analysis that we provided." - B. "We have no additional information to provide at this time because we have already provided
everything needed to support our product's approval." - C. "We have no additional information to provide at this time, but we can perform an additional analysis for
a specific safety concern, if necessary." - D. "Given the advisory committee's unanimous decision, we know that the product will not be approved,
and additional data will not make any difference."
Answer: C
NEW QUESTION 67
As a member of the product launch review committee, a regulatory affairs professional discovers a major
issue with the labeling of a product prior to production. In addition to informing the committee, which is the
BEST approach to address the issue?
- A. Abort the product launch.
- B. Correct the label text.
- C. Inform the regulatory authorities.
- D. Delay the start of product production.
Answer: C
NEW QUESTION 68
Which of the following BEST describes the purpose of the ICH?
- A. To lobby for improved industry standards for the development of new safe, effective, and high-quality
medicines for the ICH regions - B. To provide scientific evaluation of applications for international marketing authorization for safe,
effective, and high-quality medicines for the ICH regions - C. To discuss and establish common guidelines for safe, effective, and high-quality medicines for the ICH
regions - D. To protect and promote public health through the evaluation and supervision of safe, effective, and
high-quality medicines for the ICH regions
Answer: C
NEW QUESTION 69
Which of the following is the BEST approach for mitigating potential regulatory compliance issues at your
company?
- A. Develop documented procedures for regulatory compliance processes and train personnel.
- B. Document any failure to follow regulatory compliance processes in employee performance reviews.
- C. Train employees on all regulatory compliance processes using state-of-the-art systems.
- D. Train all new employees on regulatory compliance processes and assign a mentor to them.
Answer: A
NEW QUESTION 70
A company is currently marketing an implantable orthopedic medical device. The R&D department is
planning to change the material used for the implant. The R&D department states that the change does
not impact the safety and effectiveness of the product. What action should the regulatory affairs
professional take FIRST?
- A. Prepare regulatory submissions that detail the medical device's change in materials.
- B. No action is needed in this situation.
- C. Review the content of change and supporting data for the equivalency with the current material.
- D. Write a memo to file since the change does not impact product safety and effectiveness.
Answer: C
NEW QUESTION 71
In addition to protection, what parameters MUST be considered when selecting the primary package (or a
product?
- A. Safety and efficacy
- B. Volume and material
- C. Efficacy and material
- D. Compatibility and safety
Answer: D
NEW QUESTION 72
SOPs for preventive and corrective actions MUST include the procedure to eliminate which of the
following?
- A. Adverse environmental impacts
- B. Inadequate training
- C. Late and/or incorrect deliverables
- D. Causes of non-conformities
Answer: D
NEW QUESTION 73
A global company has obtained a patent in a specific country for a newly marketed product. What would
be the BEST advice In order to protect the patent in other countries?
- A. Use the Madrid system.
- B. Use the community patent system.
- C. File patents of interest in target countries.
- D. File design patents in target countries.
Answer: C
NEW QUESTION 74
A company's product was approved by a regulatory authority with the condition that further studies must
be completed prior to full approval of the product.
To minimize product-associated risk to patients during the period of conditional approval, what is the
LEAST effective way to achieve this goal?
- A. Educate patients and healthcare providers on how to use the product
- B. Promote off-label use to a carefully selected patient population.
- C. Delay product launch until required studies are completed.
- D. Label the product for use in appropriate populations.
Answer: B
NEW QUESTION 75
......
Latest RAC-GS Pass Guaranteed Exam Dumps Certification Sample Questions: https://www.lead2passed.com/RAPS/RAC-GS-practice-exam-dumps.html
